2023-507875-23-00招募中2 期
NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年1月15日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Progression-free survival rate as measured by the proportion of patients free of progression after 12-weeks of treatment (PFS: time from administration of first treatment to tumor progression or death from any cause) according to RECIST1.1
研究概览
简要总结
To determine the efficacy and safety of novel immunomodulatory strategies in TNBC patients with advanced disease
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Metastatic or incurable locally advanced triple negative breast cancer with confirmation of ER and HER2 negativity (ER <10% and HER2 IHC 0, 1+ or 2+ in the absence of amplification as determined by in situ hybridization, independent of progesterone receptor expression) on a histological biopsy of a metastatic lesion
- •Bilirubin < 1.5 x upper limit of the normal range (ULN)(except for participants with Gilbert Syndrome <3x ULN); alkaline phosphatase < 2.5 x ULN (< 5 x ULN in case of liver metastases, and < 7 x ULN N22TON, version 1.0 dd 21 July 2023 10 in case of bone metastases); transaminases (ASAT/ALAT) < 3 x ULN (and < 5 x ULN in case of liver metastases), LDH < 2xULN
- •Calculated (Cockcroft-Gault) or measured creatinine clearance > 40 mL/min
- •Signed informed consent
- •Patients with PD-L1 negative disease determined using the Combined Positivity Score (CPS<10) (Dako 22C3 immunohistochemistry) OR previously treated with anti-PD(L)1 in the (neo)adjuvant or metastatic setting (irrespective of PD-L1 status)
- •Metastatic lesion accessible for histological biopsy (Mandatory biopsies: baseline, after 1 cycle of treatment. Optional biopsies: 12-weeks, at progression).
- •18 years or older
- •WHO performance status of 0 or 1
- •Maximum of three lines of chemotherapy (including antibody-drug conjugates and PARP-inhibitors) for metastatic disease and with evidence of progression of disease.
- •Measurable or evaluable disease according to RECIST 1.1
- •Disease Free Interval (defined as time between first diagnosis or locoregional recurrence and first metastasis) longer than 1 year. This does not apply to patients with de novo metastatic disease or patients who did not receive (neo)adjuvant chemotherapy.
- •WBC ≥ 2.0x109/L, ANC ≥ 1.5 x 109/L(without G-CSF use in last 4 weeks), platelets ≥100 x 109/L, Hemoglobin ≥ 5.0 mmol/L
排除标准
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris
- •Active other cancer
- •Positive test for hepatitis B surface virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. Specified by: positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following: negative total hepatitis B core antibody (HBcAb), positive total HBcAb test followed by quantitative hepatitis B virus (HBV) DNA < 500 IU/mL. The HBV DNA test will be performed only for patients who have a negative HBsAg test, a negative HBsAb test, and a positive total HBcAb test. Specific for hepatitis C screening: positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test
- •Sign of active TB
- •Positive HIV test at screening
- •Positive EBV viral capsid antigen immunoglobulin M (IgM) test at screening
- •History of uncontrolled serious medical or psychiatric illness
- •Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- •Current pregnancy pregnancy or breastfeeding. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception: Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 90 days after the final dose of tiragolumab, 5 months after the final dose of atezolizumab. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). Per this definition, a woman with a tubal ligation is considered to be of childbearing potential. (The definition of childbearing potential may be adapted for alignment with local guidelines or regulations). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form. • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period, for 90 days after the final dose of tiragolumab. Men must refrain from donating sperm during this same period. With a pregnant female partner, men must remain abstinent or use a condom during the treatment period for 90 days after the final dose of tiragolumab to avoid exposing the embryo. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.
- •Symptomatic brain metastases, subjects with asymptomatic brain metastases are eligible. Subjects who received prior treatment for brain metastases should be free of progression on magnetic resonance imaging (MRI) for at least 4 weeks after treatment is completed and prior to first dose of study drug administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration
- •History of leptomeningeal disease localization
- •History of having received other anticancer therapies within 2 weeks of start of the study drug
- •History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
- •Known hypersensititivy to Chinese hamster ovary cell products or to any component of the atezolizumab or tiragolumab formulation
- •History of immunodeficiency, autoimmune disease, conditions requiring immunosuppression (>10 mg daily prednisone equivalents) or chronic infections. Subjects with vitiligo, diabetes mellitus type I, psoriasis not requiring systemic treatment or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement, Sjøgren’s syndrome or conditions not expected to recur in the absence of an external trigger will not be excluded from the study. Adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
- •Prior treatment with an anti-CTLA4 or anti-TIGIT antibody
- •Administration of live vaccine within 30 days of planned start of study therapy.
结局指标
主要结局
Progression-free survival rate as measured by the proportion of patients free of progression after 12-weeks of treatment (PFS: time from administration of first treatment to tumor progression or death from any cause) according to RECIST1.1
Progression-free survival rate as measured by the proportion of patients free of progression after 12-weeks of treatment (PFS: time from administration of first treatment to tumor progression or death from any cause) according to RECIST1.1
Adverse events as measured according to CTCAE v5.0 and immune-related toxicity
Adverse events as measured according to CTCAE v5.0 and immune-related toxicity
次要结局
- Response as measured by the objective response rate (ORR: complete responses or partial responses) according to iRECIST and RECIST1.1
- Clinical benefit as measured by the clinical benefit rate (CBR) according to iRECIST and RECIST1.1
- PFS measured by time to event
- Overall survival (OS: time from therapy initiation to death from any cause)
研究者
Marleen Kok
Scientific
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
研究点 (1)
Loading locations...
相似试验
招募中
不适用
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaNCT07268131Fudan University30
进行中（未招募）
1 期
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)Carcinoma, Non-Small-Cell LungTriple Negative Breast CancerNCT05460273AstraZeneca119
已完成
1 期
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBCMetastatic Triple-Negative Breast CarcinomaNCT04664829National Cancer Centre, Singapore12
招募中
2 期
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerNCT07267078Peking Union Medical College Hospital45
尚未招募
2 期
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaNCT07259122Institute of Hematology & Blood Diseases Hospital, China43